TBK1/IKK-epsilon kinase inhibitors (AstraZeneca/Acetylon/Biogen/Wuxi Biortus Biosciences)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameTBK1/IKK-epsilon kinase inhibitors (AstraZeneca/Acetylon/Biogen/Wuxi Biortus Biosciences)
Drug Alias NameTBK1/IKK-epsilon kinase inhibitors (AstraZeneca/Acetylon/Biogen Idec/Wuxi Biortus Biosciences)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase TBK1 inhibitors
TargetsSerine/threonine-protein kinase TBK1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesAstrazeneca Pharmaceuticals Lp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Pharmaceuticals LpBiogen IncAcetylon Pharmaceuticals Inc +[4] 
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A